Clinical Trials Browser

Phase 2 × Lymphoma × GSK2636771 × Clear all

NCT04439149 2025-11-21

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Phase 2 Active not recruiting

24 enrolled 9 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439188 2025-11-19

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Phase 2 Active not recruiting

35 enrolled 9 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms